ORPATHYS plus TAGRISSO hits both PFS and OS endpoints in global Phase III SAFFRON trial
HCM sits 28% above its 52-week low of $9.77 on light trading volume (0.3× avg).
Summary
Positive Phase III SAFFRON results show ORPATHYS plus TAGRISSO significantly improved both progression-free and overall survival in MET-driven EGFR-mutated lung cancer after TAGRISSO progression.
Key Events · Product Development and Regulatory · HCM
-
SAFFRON Phase III Trial Meets Both Endpoints
ORPATHYS plus TAGRISSO demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus platinum-based chemotherapy in 338 patients with MET-driven EGFR-mutated NSCLC after progression on TAGRISSO.
-
First Global Phase III Win in This Setting
SAFFRON is the first global Phase III trial to show significant PFS and OS benefits in MET-driven EGFR-mutated lung cancer after TAGRISSO progression, supporting global registrations.
-
Safety Profile Consistent
No new safety findings; the safety profile was consistent with the known profiles of each medicine.
-
Next Steps: Regulatory Submissions
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities, with AstraZeneca leading commercialization.
Analysis · HCM · Life Sciences
The SAFFRON trial is the first global Phase III study to demonstrate statistically significant and clinically meaningful improvements in both progression-free survival and overall survival for a MET inhibitor combination in EGFR-mutated lung cancer after progression on TAGRISSO. This validates the combination's efficacy beyond the China-only SACHI trial and supports global regulatory filings. The positive OS result is particularly important because overall survival is the gold standard endpoint and often harder to achieve. With AstraZeneca as partner, this could expand ORPATHYS into a multi-billion dollar global market for MET-driven resistance, a common mechanism affecting roughly one in three patients on third-generation EGFR TKIs.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $9.77 to $18.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.